Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

20161,019 citationsJournal Articlebronze Open Access

Authors

Anthony L. Cunningham · Westmead Institute for Medical Research

Himal Lal · National Yang Ming Chiao Tung University

Martina Kovac · GlaxoSmithKline (Belgium)

Roman Chlíbek · University of Defence

Shinn‐Jang Hwang · National Yang Ming Chiao Tung University

Javier Díez‐Domingo · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Olivier Godeaux

Abstract

In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

Topics & Keywords

Herpesvirus Infections and Treatments Rabies epidemiology and control Poxvirus research and outbreaks

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 11, pp. 1019-1032

DOI: 10.1056/nejmoa1603800

Field-Weighted Citation Impact: 81.52